PEPG Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of -- compared to PepGen's net margin of --. PepGen's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Edgewise Therapeutics has an analysts' consensus of $47.13 which suggests that it could grow by 78.3%. Given that PepGen has higher upside potential than Edgewise Therapeutics, analysts believe PepGen is more attractive than Edgewise Therapeutics.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Edgewise Therapeutics quarterly revenues of --. PepGen's net income of -$22.2M is higher than Edgewise Therapeutics's net income of -$39.7M. Notably, PepGen's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -- compared to PepGen's net margin of -241.28%. PepGen's return on equity of -- beat Regenxbio's return on equity of -70.45%.

PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Regenxbio has an analysts' consensus of $32.92 which suggests that it could grow by 370.24%. Given that PepGen has higher upside potential than Regenxbio, analysts believe PepGen is more attractive than Regenxbio.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.354, suggesting its more volatile than the S&P 500 by 35.35%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $21.2M. PepGen's net income of -$22.2M is higher than Regenxbio's net income of -$51.2M. Notably, PepGen's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 4.16x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to PepGen's net margin of 24.16%. PepGen's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Sarepta Therapeutics has an analysts' consensus of $178.55 which suggests that it could grow by 76.17%. Given that PepGen has higher upside potential than Sarepta Therapeutics, analysts believe PepGen is more attractive than Sarepta Therapeutics.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. PepGen's net income of -$22.2M is lower than Sarepta Therapeutics's net income of $159M. Notably, PepGen's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 44.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 5.94x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to PepGen's net margin of 31.35%. PepGen's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

PepGen has a consensus price target of $12.20, signalling upside risk potential of 419.15%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -3.31%. Given that PepGen has higher upside potential than Vertex Pharmaceuticals, analysts believe PepGen is more attractive than Vertex Pharmaceuticals.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. PepGen's net income of -$22.2M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, PepGen's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 12.09x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.